TMCnet

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

The 12 Best Stretch Mark Creams for Visibly Smoother Skin, According to Dermatologists

That being said, our experts agree that treating stretch marks early will get you the best results—and that can include ...

Johnson & Johnson: Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...
TipRanks on MSN

Arcutis Biotherapeutics presents quality of life, long-term data on ZORYVE

Arcutis Biotherapeutics (ARQT) announced that new data demonstrating ZORYVE cream 0.15% and 0.05% improved quality of life, specifically by ...